|1.||Smith, Charles D: 16 articles (12/2015 - 04/2010)|
|2.||Antoon, James W: 5 articles (02/2014 - 11/2010)|
|3.||Beckman, Barbara S: 5 articles (02/2014 - 11/2010)|
|4.||Burow, Matthew E: 4 articles (02/2014 - 11/2010)|
|5.||White, Martin D: 4 articles (09/2013 - 11/2010)|
|6.||Zhuang, Yan: 4 articles (12/2011 - 04/2010)|
|7.||Beljanski, Vladimir: 4 articles (12/2011 - 04/2010)|
|8.||Maines, Lynn W: 4 articles (04/2011 - 04/2010)|
|9.||Fitzpatrick, Leo R: 3 articles (04/2011 - 04/2010)|
|10.||Garrett-Mayer, Elizabeth: 2 articles (12/2015 - 09/2014)|
|1.||Crohn Disease (Crohn's Disease)
04/01/2010 - "The present studies test the hypothesis that an orally available SK inhibitor, ABC294640, would be effective in rodent models of Crohn's disease. "
07/01/2010 - "This conference report highlights selected presentations on the apolipoprotein E-mimetic peptide COG-112 (Cognosci Inc) for the potential treatment of Citrobacter rodentium-induced colitis; the inhibition of sphingosine kinase with ABC-294640 (Apogee Biotechnology Corp) to alleviate stress after hepatic ischemia-reperfusion injury; TLR4 targeting with NI-0101 (NovImmune SA) to prevent colitis-associated cancer; immunization against TNF with TNFalpha kinoid (Neovacs SA) for the treatment of patients with Crohn's disease; and preclinical studies with the anti-inflammatory agent minnelide (University of Minnesota) for the treatment of pancreatic cancer."
12/01/2015 - "ABC294640 is a first-in-class SK2 small-molecule inhibitor that effectively inhibits cancer cell growth in vitro and in vivo. "
01/01/2014 - "Complimentary ex vivo analyses revealed suppression of signal transduction and increased KSHV lytic gene expression within drug-treated tumors, with the latter validated in vitro through demonstration of dose-dependent viral lytic gene expression within PEL cells exposed to ABC294640. "
09/01/2013 - "Ultimately, through its inhibition of S1P formation and subsequent effects on critical survival signaling cascades, ABC294640 may prove to be a useful adjunct to help re-sensitize tumors to standard therapy. "
04/01/2011 - "Treatment with 50 mg of ABC294640/kg completely blocked tumor volume in this model. "
10/01/2010 - "Tumor multiplicity (number of tumors per animal) also decreased from 2.1 ± 0.23 tumors per animal in the AOM + DSS + vehicle group to 1.2 ± 0 tumors per animal in the AOM + DSS + ABC294640 (20 mg/kg) and to 0.8 ± 0.4 tumors per animal in the AOM + DSS + ABC294640 (50 mg/kg) group. "
|4.||Prostatic Neoplasms (Prostate Cancer)
12/01/2015 - "This study demonstrates that ABC294640 abrogates signaling pathways requisite for prostate cancer growth and proliferation. "
12/01/2015 - "Together, these pre-clinical findings support the hypotheses that SK2 activity is required for prostate cancer function and that ABC294640 represents a new pharmacological agent for treatment of early stage and aggressive prostate cancer. "
12/01/2015 - "Key findings validate that ABC294640 treatment of early-stage and advanced prostate cancer models downregulate Myc and AR expression and activity. "
12/01/2015 - "Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression."
02/01/2014 - "The novel SphK2 inhibitor, ABC294640, was used to explore SphK signaling in androgen resistant prostate cancer cell death signaling. "
12/01/2011 - "Therefore, we evaluated the effects of two SK inhibitors, ABC294640 (a SK2-specific inhibitor) and ABC294735 (a dual SK1/SK2 inhibitor), alone and in combination with sorafenib on human pancreatic adenocarcinoma (Bxpc-3) and kidney carcinoma (A-498) cells in vitro and in vivo. "
03/01/2011 - "Although combining the SK2 inhibitor, ABC294640, and sorafenib in vitro only afforded additive drug-drug effects, their combined antitumor properties in the mouse model bearing HepG2 cells mirrored effects previously observed in animals bearing kidney carcinoma and pancreatic adenocarcinoma cells. "
03/01/2011 - "We have previously reported the antitumor properties of an SK2 selective inhibitor, ABC294640, alone or in combination with the multikinase inhibitor sorafenib in mouse models of kidney carcinoma and pancreatic adenocarcinoma. "
05/01/2010 - "The present studies demonstrate that the SK2-selective inhibitor 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (ABC294640) induces nonapoptotic cell death that is preceded by microtubule-associated protein light chain 3 cleavage, morphological changes in lysosomes, formation of autophagosomes, and increases in acidic vesicles in A-498 kidney carcinoma cells. "
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||3- (4- chlorophenyl)- adamantane- 1- carboxylic acid (pyridin-4-ylmethyl)amide
|7.||sorafenib (BAY 43-9006)
|9.||Proteasome Endopeptidase Complex (Proteasome)
|2.||Heterologous Transplantation (Xenotransplantation)